



Universidad Autónoma
de Madrid

Biblos-e Archivo
Repositorio Institucional UAM

Repositorio Institucional de la Universidad Autónoma de Madrid

<https://repositorio.uam.es>

Esta es la **versión de autor** del artículo publicado en:

This is an **author produced version** of a paper published in:

Journal of Crohn's and Colitis 15.1 (2021): 35–42

DOI: <https://doi.org/10.1093/ecco-jcc/ijaa145>

Copyright: © The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn's and Colitis Organisation

El acceso a la versión del editor puede requerir la suscripción del recurso

Access to the published version may require subscription

Tofacitinib in ulcerative colitis: real-world evidence from ENEIDA registry

Short title: Tofacitinib in ulcerative colitis.

Authors: María Chaparro¹, Ana Garre¹, Francisco Mesonero², Cristina Rodríguez³, Manuel Barreiro-de Acosta⁴, Jesús Martínez-Cadilla⁵, María T. Arroyo⁶, Noemí Manceñido⁷, Mónica Sierra-Ausín⁸, Isabel Vera-Mendoza⁹, María José Casanova¹, Pilar Nos¹⁰, Carlos González-Muñoz¹¹, Teresa Martínez¹², Maia Boscá-Watts¹³, Margalida Calafat¹⁴, David Busquets¹⁵, Eva Girona¹⁶, Jordina Llaó¹⁷, María Dolores Martín-Arranz¹⁸, Marta Piqueras¹⁹, Laura Ramos²⁰, Gerard Surís²¹, Fernando Bermejo²², Ana Y Carbajo²³, Diego Casas-Deza²⁴, Agnes Fernández-Clotet²⁵, María J. García²⁶, Daniel Ginard²⁷, Ana Gutiérrez-Casbas²⁸, Luis Hernández²⁹, Alfredo J. Lucendo³⁰, Lucía Márquez³¹, Olga Merino-Ochoa³², Francisco J. Rancel³³, Carlos Taxonera³⁴, Antonio López Sanromán², Saioa Rubio³, Eugeni Domènech¹⁴ and Javier P. Gisbert¹.

¹Gastroenterology Department. Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid. Spain.

²Gastroenterology Department. Hospital Universitario Ramón y Cajal, Madrid. Spain.

³Gastroenterology Department. Complejo Hospitalario de Navarra. Pamplona. Spain.

⁴Gastroenterology Department. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela. Spain.

⁵Gastroenterology Department. Hospital Álvaro Cunqueiro- Complejo Hospitalario Universitario de Vigo. Vigo. Spain.

⁶Gastroenterology Department. Hospital Clínico Universitario Lozano Blesa and CIBERehd, IIS Aragón. Zaragoza. Spain.

⁷Gastroenterology Department. Hospital Universitario Infanta Sofía. San Sebastián de los Reyes. Spain.

⁸Gastroenterology Department. Complejo Asistencial Universitario de León. León. Spain.

⁹Gastroenterology Department. Hospital Universitario Puerta de Hierro Majadahonda. Madrid. Spain.

¹⁰Gastroenterology Department. Hospital Universitario y Politécnico La Fe and CIBERehd. Valencia. Spain.

¹¹Gastroenterology Department. Hospital Universitario Santa Creu i Sant Pau. Barcelona. Spain.

¹²Gastroenterology Department. Hospital Virgen de la Luz. Cuenca. Spain.

¹³Gastroenterology Department. Hospital Clinico de Valencia and Universitat de Valencia. Valencia. Spain

¹⁴Gastroenterology Department. Hospital Universitari Germans Trias i Pujol and CIBERehd, Badalona, Barcelona. Spain.

¹⁵Gastroenterology Department. Hospital Universitario de Gerona Dr Josep Trueta, Girona. Spain.

¹⁶Gastroenterology Department. Hospital General Universitario de Elche, Alicante. Spain.

¹⁷Gastroenterology Department. Hospital Sant Joan de Déu, Althaia, Xarxa Assistencial Universitària de Manresa, Barcelona. Spain.

¹⁸Department of Gastroenterology of La Paz Hospital, Madrid, Spain. Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz Hospital, Madrid, Spain.

¹⁹Gastroenterology Department. Consorci Sanitari de Terrasa, Barcelona. Spain.

²⁰Gastroenterology Department. Hospital Universitario de Canarias. Islas Canarias. Spain.

²¹Gastroenterology Department. Hospital de Bellvitge and IDIBELL, L'Hospitalet. Spain.

²²Gastroenterology Department. Hospital Universitario de Fuenlabrada. Instituto de Investigación Sanitaria del Hospital La Paz (IdiPaz). Madrid, Spain.

²³Gastroenterology Department. Hospital Universitario Río Hortega, Valladolid. Spain.

²⁴Gastroenterology Department. Hospital Universitario Miguel Servet. Zaragoza. Spain.

²⁵Gastroenterology Department. Hospital Clínic de Barcelona, Barcelona. Spain.

²⁶Gastroenterology Department. Hospital Universitario Marqués de Valdecilla and IDIVAL. Santander. Spain.

²⁷Gastroenterology Department. Hospital Universitario Son Espases. Palma de Mallorca. Spain.

²⁸Gastroenterology Department. Hospital General Universitario de Alicante and CIBERehd. Alicante. Spain.

²⁹Gastroenterology Department. Hospital Santos Reyes de Aranda del Duero. Burgos. Spain.

³⁰Gastroenterology Department. Hospital General de Tomelloso, Instituto de Investigación Sanitaria Princesa (IIS-IP) and CIBEREHD Ciudad Real. Spain.

³¹Gastroenterology Department. Hospital del Mar and Institut Hospital del Mar d'Investigacions Mèdiques. Barcelona. Spain.

³²Gastroenterology Department. Hospital Universitario de Cruces. Vizcaya. Spain.

³³Gastroenterology Department. Complejo Hospitalario de Palencia. Palencia. Spain.

³⁴Gastroenterology Department. Hospital Clínico San Carlos and IdISSC, Madrid. Spain.

ABBREVIATIONS: ulcerative colitis, UC; inflammatory bowel disease, IBD; anti-tumour necrosis factor alpha, anti-TNF; C-reactive protein, CRP; standard deviation, SD; interquartile range, IQR.

KEY WORDS: tofacitinib, ulcerative colitis.

AUTHOR CONTRIBUTIONS

María Chaparro and Javier P. Gisbert: Study design, data collection, data analysis, data interpretation, writing the manuscript.

Ana Garre: Data monitoring.

Rest of authors: Patient inclusion.

All authors approved the final version of the manuscript.

María Chaparro and Javier P. Gisbert are the guarantors of the article.

FUNDING: The ENEIDA registry of GETECCU is supported by Biogen, Janssen, Takeda and Pfizer.

CORRESPONDENCE

María Chaparro, M.D., Ph.D.

Inflammatory Bowel Disease Unit

Department of Gastroenterology

University Hospital La Princesa

Diego de León, 62. 28006 Madrid, Spain

Tel.: 34-913093911; Fax: 34-915204013

e-mail: mariachs2005@gmail.com

CONFLICTS OF INTEREST

M Chaparro has served as a speaker, or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma.

M Barreiro-de Acosta has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Hospira, Takeda, Janssen, Kern, Ferring, FaesFarma, ShirePharmaceuticals, Dr. FalkPharma, Chiesi, GebroPharma, OtsukaPharmaceuticals, and TillottsPharma.

Isabel Vera-Mendoza has served as speaker, consultant and advisory member for and has received funding for: MSD, Abbvie, Pfizer, Ferring, Shire Pharmaceuticals, Takeda y Jannsen.

Teresa Martínez has served as speaker, consultant and advisory member for and has received funding for Janssen, Abbvie, Pfizer, Amgen, Takeda, Tillotts Pharma, Shire.

JP Gisbert has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Roche, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Vifor Pharma.

E Domènech has served as a speaker, or has received research or education funding or advisory fees from MSD, AbbVie, Takeda, Kern Pharma, Pfizer, Janssen, Celgene, Adacyte Therapeutics, Otsuka Pharmaceuticals, Ferring, Shire Pharmaceuticals, Tillots, Thermofisher, Grifols, Gebro.

Rest of authors have nothing to declare.

ABSTRACT

Aim: To evaluate the effectiveness and safety of tofacitinib in ulcerative colitis (UC) in real life.

Methods: Patients from the prospectively maintained ENEIDA registry treated with tofacitinib due to active UC were included. Clinical activity and effectiveness were defined based on Partial Mayo Score (PMS). Short-term response/remission was assessed at week 4, 8 and 16.

Results: A total of 113 patients were included. They were exposed to tofacitinib for a median time of 44 weeks. Response and remission at week 8 were 60% and 31%, respectively. In multivariate analysis, higher PMS at week 4 [odds ratio (OR)=0.2; 95% confidence interval (CI)=0.1-0.4] was the only variable associated with lower likelihood of achieving remission at week 8. Higher PMS at week 4 (OR=0.5; 95%CI=0.3-0.7) and higher PMS at week 8 (OR=0.2; 95%CI=0.1-0.5) were associated with lower probability of achieving remission at week 16. A total of 45 patients (40%) discontinued tofacitinib over time. Higher PMS at week 8 was the only factor associated with higher tofacitinib discontinuation [Hazard ratio=1.5; 95%CI=1.3-1.6]. A total of 34 patients had remission at week 8; of these, 65% had relapsed 52 weeks after achieving remission; the dose was increased to 10 mg/12 h in 9 patients, and 5 of them reached remission again. Seventeen patients had adverse events.

Conclusions: Tofacitinib is effective and safe in UC patients in real practice, even in a highly refractory cohort. A relevant proportion of patients discontinue the drug over time, mainly due to primary failure.

Introduction

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) with a relapsing-remitting pattern that causes an increased frequency of bowel movements and bloody diarrhoea, leading to organ damage and impaired quality of life^{1, 2}. The primary goals of therapy in UC are reducing the mucosal inflammation and maintaining symptom remission, though these aims are not achieved in all patients¹⁻³.

In the last two decades, the introduction of biological therapies changed the natural history of UC. Remission and response rates achieved with current biological treatment [anti-tumour necrosis factor alpha (anti-TNF) and vedolizumab] are around 20-35% and 60-70%, respectively^{4, 5}. Nevertheless, up to 30% of patients do not respond to anti-TNF drugs (primary non-responders), and about 10-20% per year lose response after an initial improvement (secondary non-responders), thereby requiring a dose escalation or a switch to another drug class⁴⁻¹¹. In addition to TNF, there are several other cytokine pathways involved in the development of UC, which have led to the development of target specific drugs.

Tofacitinib is an oral synthetic small-molecule Janus kinase (JAK) inhibitor. The JAKs are downstream signalling molecules of a large number of cytokine pathways involved in IBD^{12, 13}. The efficacy and safety of tofacitinib have been demonstrated in clinical trials in patients with moderate to severe UC, and this drug has recently been approved by the European Medicines Agency for the treatment of this condition. The results of phase III clinical trials have confirmed the superiority of tofacitinib over placebo in induction treatment and maintenance of clinical remission in patients with moderate to severe UC¹⁴.

However, the experience with tofacitinib in clinical practice, both in terms of effectiveness and safety, is still limited. The use of drugs in clinical trials differs from that of the routine clinical practice in several aspects such as patient characteristics (patients are frequently more refractory to treatments and with more comorbidities in real-life practice), thus limiting the generalization of clinical trial results. Non-interventional studies, on the other hand, provide complementary information to clinical trials on the effectiveness of treatments in real clinical practice settings.

ENEIDA project is a prospectively maintained registry, which includes UC patients treated with several therapeutic options in daily practice. This registry offers the opportunity of evaluating the real-life effectiveness and safety of tofacitinib in UC patients. Our aim was to assess the short-term effectiveness of tofacitinib in UC, to evaluate the durability of tofacitinib treatment and the cumulative incidence of relapse over time, to identify predictive factors of short and long-term response, and to assess the safety profile of tofacitinib in a clinical practice setting. Our results provide data that will be useful for the management of UC patients in real life and will help to position tofacitinib in the therapeutic algorithm of UC.

Methods

Study design

This was an observational, prospective and multicentre study carried out with data from ENEIDA registry, a large prospectively maintained Spanish database promoted by the Spanish Working Group on Crohn's and ulcerative colitis (GETECU), initiated in 2007, which in December 2019 included approximately 60,000 patients from 82 centres. Patients aged 18 years or older, diagnosed with UC, who received at least one dose of tofacitinib due to active disease (Partial Mayo Score [PMS] ≥ 2) were included¹⁵. Patients who had received tofacitinib for an indication different from UC, those with colonic resection and those who started the treatment less than 8 weeks before data analysis were excluded. ENEIDA registry was approved by Research Ethics Committees in all participating centres. Written informed consent to participate in the ENEIDA project was obtained from all patients.

Data collection

Patient demographic and clinical characteristics were collected and included: sex, age, colitis extent, extraintestinal manifestations, previous surgery for UC, concurrent use of immunomodulators and steroids, previous treatments for UC and biological markers [C-reactive protein (CRP) or faecal calprotectin]. Start of treatment and change of tofacitinib dose were also registered. Endoscopic assessment information was recorded when available and graded as quiescent, mild, moderate or severe according to the endoscopic subscore of the Mayo index. In addition, all adverse events during the follow-up period were recorded.

Patients were followed-up until last administration of tofacitinib or last visit, whichever came first. Data were remotely monitored to assess data quality.

Evaluation of effectiveness

Short-term effectiveness was assessed at week 4, 8 and 16. Long-term effectiveness was evaluated every time the patients came to the clinic for disease monitoring until last administration of tofacitinib or last visit, whichever came first. Clinical activity and effectiveness were assessed based on PMS (including stool frequency, rectal bleeding and physician's global assessment) ranging from 0 to 9.

Definitions

Active disease: Active disease was defined as a score ≥ 2 points in PMS. When endoscopy was available, the severity was graded by local investigators as quiescent, mild, moderate or severe.

Severity of clinical activity: The severity of clinical activity was rated based on the PMS: <2 remission, 2-4 mild, 5-7 moderate, and >7 severe.

Evaluation of response: Clinical remission or response was determined by PMS calculated at baseline and at week 4, 8 and 16. Clinical remission was defined as a $\text{PMS} < 2$. Clinical response was defined as a reduction in PMS ≥ 3 points and at least 30% from baseline, with a decrease ≥ 1 point in the rectal bleeding subscale.

Relapse: Relapse was defined as worsening of patient's symptoms coupled with endoscopic, radiographic or serologic (CRP or faecal calprotectin) evidence of inflammation that led the physician to escalate the dose of

treatment, add another medication, change to other drug or change treatment to surgery.

Statistical analysis

For categorical variables percentages were calculated (with their 95% confidence intervals). The descriptive analysis of quantitative variables calculated the mean and standard deviation (SD), or the median and interquartile range (IQR), depending on whether they were normally distributed or not. In the univariate analysis, categorical variables were compared using Chi-square (χ^2) test and quantitative variables using the appropriate test. Short-term effectiveness was evaluated at week 8; clinical remission at week 8 was the main variable. Nevertheless, the proportion of patients with clinical remission or clinical response at week 4 and 16 was also evaluated. Variables associated with the likelihood of treatment response after the induction, were identified using a logistic regression model. Last observation carried forward method was used to impute missing data for the short-term evaluation (weeks 4, 8 and 16).

The Kaplan-Meier method, where patients who discontinued tofacitinib for any reason were rightly censored at the time of discontinuation, was used to evaluate the long-term durability of tofacitinib treatment. In addition, we analysed the cumulative incidence of relapse among patients who reached remission at week 8. Any differences between survival curves were evaluated with the log-rank test. Stepwise multivariate analysis using the Cox model was performed to identify factors associated with tofacitinib discontinuation or relapse over time. In the log-rank test and in the multivariate analysis, statistical significance was considered when $p < 0.05$.

Results

Patient characteristics

A total of 113 patients were included. The main characteristics of the study population are summarised in table 1. The majority of patients (70%) had extensive colitis. All patients had been previously exposed to anti-TNF agents, 89% to vedolizumab, and 4% to ustekinumab. Ninety-five (84%) patients had received only anti-TNF agents, 13 (11.5%) anti-TNF agents and vedolizumab, and 5 (4.5%) patients anti-TNF agents, vedolizumab and ustekinumab before tofacitinib treatment. At baseline, 11% of patients were under immunomodulators (9 patients under thiopurines and 4 under methotrexate) and 48% under steroids. A total of 18 patients were under steroids at week 4, 14 at week 8, and 9 patients at week 16 (of them, only 3 were in clinical remission at week 16).

The median partial Mayo score at the start of tofacitinib treatment was 6 (IQR=6-8). Sixty-seven percent of patients had endoscopic assessment of disease activity before starting tofacitinib treatment: 65% had severe, and 29% moderate activity. In addition, one-third of patients had anaemia, two-thirds had CRP levels over the normal limit, and median faecal calprotectin at baseline was 1,499 µg/g.

Patient flow-chart, including tofacitinib dose adjustments, discontinuations and reasons for discontinuations is shown in figure 1. Ninety-four percent of patients started tofacitinib treatment with 10 mg/12 h; two of them had to interrupt the treatment before week 4 due to primary non-response. A total of 101 patients reached week 8 under tofacitinib treatment; 92% of them with the 10 mg/12 h dose; twenty-seven patients changed to the maintenance dose (5

mg/12 h). Seventy-seven patients reached week 16 under tofacitinib treatment, 28 of them under 10 mg/12 h. Four patients were changed to the maintenance dose at week 16.

Short-term effectiveness

In the short-term, 18 (16%) patients reached clinical remission at week 4, 34 (31%) at week 8, and 33 (32%) at week 16. With respect to clinical response (including both patients with response and with remission), 45 (40%) had response at week 4, 66 (60%) at week 8, and 59 (57%) at week 16 (Figure 2).

Patients who achieved remission at week 8 had, at baseline, lower proportion of severe endoscopic activity (46% vs. 74%, $p<0.05$) and lower CRP (0.6 mg/dL vs. 1.3 mg/dL, $p<0.05$) than patients who did not achieve remission. Other characteristics, such as disease extension, treatment with steroids at baseline or number of previous biologicals, were similarly distributed in both groups. In addition, patients who achieved remission at week 8 had lower CRP at week 4 (0.13 mg/dL vs. 1.2 mg/dL, $p<0.05$) and lower PMS (1 vs. 5, $p<0.05$) than patients who did not achieve remission. In the multivariate analysis, higher PMS at week 4 (OR=0.2; 95%CI=0.1-0.4) was the only variable associated with the likelihood of achieving remission at week 8 (the higher PMS, the lower probability of achieving remission).

Twenty percent of patients without remission at week 4, and 12% of those without remission at week 8, achieved remission at week 16. Clinical characteristics at baseline, including PMS, CRP concentration, haemoglobin, faecal calprotectin, number of previous biological treatments, endoscopic activity or concomitant treatment with immunomodulators or steroids were

similar in patients with or without remission at week 16. Patients who achieved remission at week 16 had lower proportion of elevated CRP both at week 4 (37% vs. 67%, $p<0.05$) and at week 8 (24% vs. 51%, $p<0.02$) than those who did not achieve remission at week 16. In addition, patients in clinical remission at week 16 had lower PMS both at week 4 (2 vs. 4, $p<0.01$) and at week 8 (1 vs. 4, $p<0.01$) than those without remission at week 16. In the multivariate analysis, higher PMS at week 4 ($OR=0.5$; $95\%CI=0.3-0.7$) and higher PMS at week 8 ($OR=0.2$; $95\%CI=0.1-0.5$) were associated with lower probability of achieving remission at week 16.

Tofacitinib survival

A total of 45 patients (40%) discontinued tofacitinib over time (median of exposure to tofacitinib was 44 weeks; $IQR=30-66$ weeks). Cumulative discontinuation rate was 34% and 46% at 24 and 52 weeks, respectively (figure 3). The reasons for tofacitinib discontinuation were: primary non-response in 29 patients (26%), adverse events in 7 patients (6%), relapse in 6 patients (5%), partial response in 2 patients (2%) and pregnancy wish in 1 patient (1%). PMS at week 8 was the only factor associated with tofacitinib discontinuation ($Hazard\ Ratio=1.5$; $95\%CI=1.3-1.6$).

Long-term effectiveness

A total of 34 patients were in remission at week 8; 13 (38%) relapsed during follow-up (figure 4); the dose was increased to 10 mg/12 h in 9 patients, and 5 of them reached remission again. No factors associated with relapse over time were identified.

Adverse events

Seventeen patients (15%) had adverse events during follow-up, some of them more than one adverse event: 4 patients had hypercholesterolemia, 1 herpes zoster (single dermatome involvement and resolved without postherpetic neuralgia), 1 herpes simplex, 3 infections, 2 dyspnoea, 1 neoplasia, 1 lymphopenia, 1 headache, 1 hypertriglyceridemia and 4 others. With respect to infections, two patients had salmonella gastrointestinal infections (leading to tofacitinib discontinuation) and the third patient a criptoglandular anorectal abscess (treated with drainage and antibiotics; tofacitinib was maintained). No thromboembolic events were reported. Seven patients (6%) presented adverse events that led to treatment discontinuation. The first patient developed high fever and headache with doubtful meningeal signs and was empirically treated with antiviral drugs although microbiological tests were always negative. The suspicion was a serious viral infection but the agent was not identified. After withdrawing treatment and completing valganciclovir treatment all disappeared. Two patients presented with severe salmonella gastrointestinal infections and were recovered without sequelae. Another patient had severe abdominal pain without identifying the cause. The fifth patient presented dyspnea clearly associated with the drug intake. The sixth patient presented herpes zoster infection, dyspnea and dizziness. Finally, a patient developed a metastatic breast cancer probably related to a high immunosuppressive load before being treated with tofacitinib.

Discussion

To our knowledge, this is the largest cohort among the few published real-life studies of UC patients treated with tofacitinib. Our results provide new information about the effectiveness of tofacitinib in real-life, which is of great value to position this treatment in clinical practice.

Firstly, our results support that tofacitinib is effective in clinical practice in a refractory UC population (all patients had previously failed treatment with biological therapies such as anti-TNF drugs or vedolizumab). Thus, at week 8, approximately 1/3 of patients achieved remission and 2/3 had response. In addition, after the first 4 weeks almost 20% of patients achieved clinical remission and 40% of them responded to treatment, confirming the early response to tofacitinib, which was previously observed in the OCTAVE trials¹⁶. However, despite the fast mechanism of action of tofacitinib, some patients need longer to reach remission. In this respect, in our study, patients without remission at week 4 did benefit from continuing the treatment: 20% of patients without remission at week 4, and 12% of those without remission at week 8, achieved remission at week 16. Similarly to our results, previous studies showed that a substantial proportion of non-responders to an initial 8-week course of tofacitinib with a twice-daily dose of 10 mg respond to an additional extended induction course of 8 weeks^{17, 18}.

Our results are consistent with those from pivotal studies. In this respect, in a phase II trial with patients who received 10 mg twice-daily, at week 8, clinical response and remission occurred in 61% and 48% of the patients, respectively¹². In the OCTAVE induction 1 and 2 trials, remission at week 8 was achieved by 18% and 17% of the patients, respectively^{14, 19}.

With respect to real-life studies, short-term effectiveness of tofacitinib in refractory UC was evaluated in a retrospective study conducted by Lair-Mehiri et al. in 38 refractory UC patients, previously treated with anti-TNF (100%) and vedolizumab (97%)²⁰. At week 14, steroid-free remission was achieved in 32% and clinical response in 45% of patients. Similarly, the other published cohort on the effectiveness of tofacitinib in real life included 58 UC patients, who previously failed anti-TNF (93%) and anti-integrin (81%); this study showed that remission at week 8 (defined as complete resolution of clinical symptoms) was achieved in 33% of the patients, and clinical response (defined as symptomatic improvement from baseline) in 36%²¹.

Furthermore, we detected predictive factors of remission that would allow us to identify the subset of patients who will benefit the most from the treatment. In this regard, we observed that early response at weeks 4 and 8 indicated higher probability of remission at week 16; thus, patients with more severe disease as measured by PMS at week 4 and week 8 were less likely to achieve remission at week 16. The other two published cohorts of patients with UC treated with tofacitinib did not identify predictive factors of response to the treatment, probably due to their limited sample size^{20, 21}. In our cohort, patient characteristics at baseline, such as PMS, CRP concentration, faecal calprotectin concentration or number of previous biologicals were not associated with the likelihood of remission at week 8. In line with our results, in the OCTAVE 1 and 2 trials, tofacitinib efficacy was consistent regardless of CRP levels at baseline, baseline steroid use or previous exposure to anti-TNF¹⁴. Based on these results, tofacitinib might be a good therapeutic option also in patients with previous failure to anti-TNF.

On the other hand, a significant proportion of patients (40%) discontinued the drug over time (cumulative discontinuation rate was 34% and 46% at 24 and 52 weeks, respectively), mainly due to primary failure (26%) followed by adverse events (6%), relapse (5%) and partial response (2%). In line with our results, Weisshof et al. reported discontinuation of tofacitinib in 26/58 (45%) patients during a median follow-up period of 10 months, due to poor response or adverse events²¹, while Lair-Mehiri et al. reported a discontinuation rate of 42% (16/38) in a follow-up period of 41 weeks, mostly occurring within 24 weeks and due to lack of effectiveness (7 disease worsenings and 4 non-responses)²⁰.

Tofacitinib is a small molecule with lack of immunogenicity as opposed to biological agents, which are large protein-based molecules. It is known that the formation of antibodies against biological drugs could affect their long-term efficacy²². It is still unclear whether the response to tofacitinib is lasting or long-term response could be lost in patients treated with this drug. We observed that 38% of patients who achieved remission at week 8 relapsed over time (median of exposure to tofacitinib, 44 weeks). The durability of remission under tofacitinib treatment was also evaluated in the OCTAVE Sustain trial, where patients were included to assess whether tofacitinib could be used to maintain remission¹⁴. For patients already in remission at maintenance trial entry, sustained remission at week 52 occurred in 35% of patients in the 5 mg group and 47% in the 10 mg group. In our study, after relapsing, tofacitinib dose was escalated from 5 mg/12 h to 10 mg/12 h in 9 patients; 5 of them reached remission again after increased tofacitinib dose. Sands et al. analysed the efficacy of dose escalation of tofacitinib (to 10 mg/12 h) in patients who lost response while being treated with tofacitinib 5 mg/12 h as maintenance therapy

in the OCTAVE open trial; at month 12, 75% of patients maintained remission²³. After dose escalation, 35% and 49% recaptured remission at month 2 and 12, respectively. Thus, dose escalation might be an option in patients relapsing under the maintenance dose.

Of note, the European Medicines Agency advised that maintenance doses of 10 mg twice-daily should not be used in patients with UC who are at high risk of blood clots unless there is no suitable alternative treatment, due to the dose-dependent increased risk of blood clots in the lungs and deep veins of patients who are already at high risk²⁴. This recommendation should be taken into consideration when deciding the treatment schedule with tofacitinib. Nevertheless, data about the dose-dependent increased risk of thromboembolic events come from studies in rheumatoid arthritis patients, and particularly in patients over 50 years of age, whereas the aforementioned risk has not been confirmed in UC patients yet²⁵. In this respect, in a post-hoc analysis of the OCTAVE trials, only 5 patients developed thromboembolic events (1 deep venous thrombosis and 4 pulmonary embolisms), all of them had risk factors for venous thromboembolism and were predominantly under the 10 mg/12 h dose²⁶. In our study, the safety profile of tofacitinib was in line with previous data²⁷, and no thromboembolic events were reported. However, it should be acknowledged that the analysis is limited by small sample size and limited drug exposure, and therefore more data are needed.

Our study has some limitations. First of all, although ENEIDA registry is prospectively completed, efficacy outcomes are rated on the basis of clinical subjective assessment. To overcome the potential heterogeneity in clinical assessment, clinicians were asked to provide PMS score values at every visit.

In addition, we could not evaluate mucosal healing. However, this reflects what happens in clinical practice, where endoscopy studies are generally not carried out if patients have good response after induction. Information about concomitant steroids is not easy to understand in real world evidence studies where the follow-up is not pre-established per protocol (follow-up time was different in each patient). Unfortunately, there is no available information on the precise dose of steroids during tofacitinib treatment. Finally, all of our patients had previously failed treatment with biological agents and therefore we could not assess the impact of biological exposure on tofacitinib effectiveness.

On the other hand, our study has several strengths. First of all, this is the largest study published up to now on the effectiveness of tofacitinib on UC in real-life. Clinical activity was categorised based on PMS, which has acceptable correlation with the presence of inflammation²⁸ and we also included other objective parameters such as CRP levels or faecal calprotectin concentration. Finally, we could assess durability of tofacitinib treatment, relapse rate and response to dose escalation.

In conclusion, tofacitinib is relatively effective, providing a rapid therapeutic effect in UC patients in real practice, even in a highly refractory cohort. A relevant proportion of patients discontinue the drug over time, mainly due to primary failure. A relevant proportion of the patients who achieve remission after induction relapse over time, although dose escalation is able to recapture remission in over 50% of them. Finally, safety was consistent with the known profile of tofacitinib.

REFERENCES

1. Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. *Best Pract Res Clin Gastroenterol* 2018; 32-33: 59-69.
2. Chaparro M, Gisbert JP. Maintenance therapy options for ulcerative colitis. *Expert Opin Pharmacother* 2016; 17: 1339-1349.
3. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. *J Crohns Colitis* 2017; 11: 769-784.
4. Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment (anti-TNF, vedolizumab and ustekinumab) in patients with inflammatory bowel disease: from basic science to clinical practice. *J Crohns Colitis* 2019: In press.
5. Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, et al. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. *Aliment Pharmacol Ther* 2018; 48: 839-851.
6. Taxonera C, Iglesias E, Munoz F, Calvo M, Barreiro-de Acosta M, Busquets D, et al. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. *Dig Dis Sci* 2017; 62: 481-490.
7. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. *Am J Gastroenterol* 2009; 104: 760-767.
8. Chaparro M, Andreu M, Barreiro-de Acosta M, Garcia-Planella E, Ricart E, Domenech E, et al. Effectiveness of infliximab after adalimumab failure in Crohn's disease. *World J Gastroenterol* 2012; 18: 5219-5224.
9. Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. *Inflamm Bowel Dis* 2012; 18: 2026-2033.
10. Chaparro M, Panes J, Garcia V, Manosa M, Esteve M, Merino O, et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. *J Clin Gastroenterol* 2011; 45: 113-118.
11. Chaparro M, Panes J, Garcia V, Merino O, Nos P, Domenech E, et al. Long-term durability of response to adalimumab in Crohn's disease. *Inflamm Bowel Dis* 2012; 18: 685-690.
12. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. *N Engl J Med* 2012; 367: 616-624.
13. Panes J, Gisbert JP. Efficacy of tofacitinib treatment in ulcerative colitis. *Gastroenterol Hepatol* 2019; 42: 403-412.
14. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med* 2017; 376: 1723-1736.
15. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. *Inflamm Bowel Dis* 2008; 14: 1660-1666.
16. Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, et al. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. *Clin Gastroenterol Hepatol* 2019; 17: 139-147.
17. Varyani F, Argyriou K, Phillips F, Tsakiridou E, Moran GW. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data. *Drug Des Devel Ther* 2019; 13: 4091-4105.
18. Rubin D, Dubinsky M, Lukas M, Quirk D, Nduaka CI, Maller E, et al. Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders. *J Crohns Colitis* 2019; 13: S049-S050.
19. Sandborn WJ, Su C, Panes J. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med* 2017; 377: 496-497.


20. Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. *Dig Liver Dis* 2019.
21. Weissshof R, Aharoni Golan M, Sossenheimer PH, El Jurdi K, Ollech JE, Pekow J, et al. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. *Dig Dis Sci* 2019; 64: 1945-1951.
22. Chaparro M, Guerra I, Munoz-Linares P, Gisbert JP. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. *Aliment Pharmacol Ther* 2012; 35: 971-986.
23. Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, et al. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. *Aliment Pharmacol Ther* 2020; 51: 271-280.
24. European Medicines Agency. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. 2019. <https://http://www.ema.europa.eu/en/medicines/human/referrals/xeljanz>. Accessed January 27, 2020.
25. Food and Drug Administration. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). 2019. <https://http://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and>. Accessed January 27, 2020.
26. Sandborn WJ, Panes J, Sands BE, Reinisch W, Su C, Lawendy N, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. *Aliment Pharmacol Ther* 2019; 50: 1068-1076.
27. Sandborn WJ, Panes J, D'Haens GR, Sands BE, Su C, Moscariello M, et al. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. *Clin Gastroenterol Hepatol* 2019; 17: 1541-1550.
28. Pagnini C, Menasci F, Festa S, Rizzatti G, Corleto VD, Delle Fave MM, et al. Application of clinical indexes in ulcerative colitis patients in regular follow-up visit: correlation with endoscopic 'mucosal healing' and implication for management. Preliminary results. *Eur Rev Med Pharmacol Sci* 2015; 19: 3674-3681.

Table 1. Characteristics of the study population.

Median age (SD) (years)	46 (1.3)
Median time of follow-up (IQR) (weeks)	44 (30-66)
Male gender, n (%)	65 (58)
UC extent	
Proctitis, n (%)	4 (4)
Left-sided colitis, n (%)	30 (26)
Extensive colitis, n (%)	79 (70)
Median partial Mayo score at baseline (IQR)	6 (6-8)
Endoscopic assessment at baseline, n (%)	76 (67)
Moderate activity, n (%)	22 (29)
Severe activity, n (%)	50 (65)
CRP above the normal limit at baseline, n (%)	73 (68)
Anaemia at baseline, n (%)	36 (32)
Median faecal calprotectin at baseline (SD) (µg/g)	1,499 (1,233)
Prior biological treatment, n (%)	113 (100)
Anti-TNF, n (%)	113 (100)
Vedolizumab, n (%)	98 (89)
Ustekinumab, n (%)	5 (4)
Prior number of biological agents	
1-2 previous biologics, n (%)	34 (31)
≥3 previous biologics, n (%)	79 (69)
Concomitant immunosuppressants, n (%)	13 (11)
Steroids during induction, n (%)	54 (48)

Standard deviation, SD; ulcerative colitis, UC; interquartile range, IQR; C-reactive protein, CRP.

Figure 1. Flow-chart of patients, including tofacitinib dose adjustment, discontinuations and reasons for discontinuation.



Not all patients reached all the evaluation moments because, even if they maintained the treatment, they may not have had time since the beginning of the treatment.

Figure 2. Short-term effectiveness of tofacitinib in ulcerative colitis (last-observation-carried-forward method).




Figure 3. Survival curve of patients maintaining tofacitinib treatment over time.





Figure 4. Survival curve of patients relapsing over time (from week 8 and including only patients in remission at that time).



*Relapse was defined as worsening of clinical symptoms plus endoscopic inflammation, elevated faecal calprotectin or elevated C-reactive protein.